NCT03009214已完成1 期
A Safety, Tolerability and Pharmacokinetic Dose Escalation and Expansion, Phase I/Ib Study of AMC303 as Monotherapy in Patients With Advanced or Metastatic, Malignant Solid Tumour of Epithelial Origin
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- amcure GmbH
- 入组人数
- 55
- 试验地点
- 7
- 主要终点
- Safety and tolerability of AMC303
研究概览
简要总结
This is a two part Phase I/Ib, open-label, non-randomized and multi-center, dose escalation study with a 3+3 design (Part 1) and an expansion cohort at the Maximum Tolerated Dose (MTD)/Recommended Phase 2 Dose (RP2D) (Part 2). If MTD is not reached in Part 1, RP2D will be determined after completion of Part 1 considering safety and tolerability, also beyond the dose limiting toxicity (DLT) period, pharmacokinetic (PK) and pharmacodynamic (PD) results.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Histologically confirmed and documented, advanced or metastatic, accessible malignant solid tumour of epithelial origin and for which no standard therapy exists or standard therapy has failed.
- •Presence of a measurable tumour according to RECIST 1.
- •At least 4 weeks from the completion of any previous cytotoxic chemotherapy, 6 weeks from biological therapy (monoclonal antibodies) or cancer immunotherapy (immune checkpoint modulators) or 2 weeks from targeted therapy (receptor tyrosine kinase inhibitors) at time of administration of AMC
- •Male or female patients, at least 18 years of age
- •Eastern Cooperative Oncology Group (ECOG) performance status 0 - 1
- •Life expectancy > 12 weeks.
- •Adequate haematological function defined as
- •Absolute neutrophil count (ANC) > 1,500 / µL
- •Platelets > 100,000 / µL
- •Haemoglobin > 9 g /dL.
- •Adequate renal function defined as
- •Glomerular filtration rate (GFR) ≥ 50 ml/min according to local laboratory standard or
- •Serum creatinine < 1.5 mg / dL.
- •Adequate hepatic function defined as
- •Total bilirubin < 1.5x institutional upper limit of normal (ULN)
- •AST, ALT ≤ 3x institutional ULN or < 5x institutional ULN if known hepatic metastases
- •Alkaline phosphatase < 3x institutional ULN or < 5x institutional ULN if known hepatic metastases.
- •Patient may have central nervous system (CNS) involvement if metastases have been treated and are stable at least 4 weeks after completion of radiation therapy and/or surgery. Stable disease is defined as absence of new neurological symptoms, absence of the need for steroid therapy and radiographic confirmation of stable disease. Radiographic confirmation of stable disease 4 weeks after completion of radiation therapy is not required unless indicated by neurological examination.
- •All female subjects will be considered to be of childbearing potential unless they are postmenopausal (at least 12 months consecutive amenorrhea, in the appropriate age group and without other known or suspected cause), or have been sterilized surgically. For female participants and female partners of childbearing potential, willingness and able to use two forms of highly effective contraception methods (e.g. oral contraceptive and condom, intra-uterine device and condom) while on study and for 30 days after the last study treatment. For male participants or male partners of childbearing potential, willingness and able to use two forms of highly effective contraception methods (e.g. oral contraceptive and condom, intra-uterine device and condom,) while on study and for three months after the last study treatment.
- •Provision of signed Informed Consent prior to any study related procedure being performed
排除标准
- •Receipt of any other investigational agent within 28 days prior to first administration of AMC
- •Investigational monoclonal antibodies must not be given within 6 weeks before treatment start with AMC
- •Enrolment in another clinical study with an investigational drug
- •Presence of residual toxicities of CTCAE Grade > 1 after prior anti-tumour therapy within 2 weeks of first treatment with AMC303 with the exception of Grade 3 alopecia and infusion site reactions
- •Severe concurrent illness or psychiatric illness/social situation that would limit compliance with study requirements
- •Anticipation of major surgical procedures within first 4 weeks of first dose
- •Pregnancy or breast-feeding as determined by a serum pregnancy test (β-HCG) at screening prior to administration of AMC303 and willingness to father a child or to become pregnant
- •Untreated acute infectious disease
- •Patient is known to be suffering from Acquired Immune Deficiency Syndrome (AIDS) or is known to be HIV seropositive without AIDS defining disease
- •Known chronic hepatitis B or C.
- •History of allergic reactions attributed to compounds of similar chemical or biological composition to AMC
- •Evidence of any other medical conditions that in the opinion of the investigator may interfere with the planned treatment, affect patient compliance or place the patient at high risk from treatment-related complications
- •Previous malignant disease other than the target malignancy to be investigated within the last 5 years with the exception of basal or squamous carcinoma of the skin or cervical carcinoma in situ
- •Legal incapacity or limited legal capacity
研究组 & 干预措施
AMC303
Experimental
cohorts will receive ascending doses of AMC303 as intravenous infusion
Planned doses are:
0.1 mg/kg, 0.5 mg/kg, 1.5 mg/kg, 4 mg/kg, 10 mg/kg and 20 mg/kg
干预措施: AMC303 (Drug)
结局指标
主要结局
Safety and tolerability of AMC303
时间窗: 6 months
Number of patients with treatment-related adverse events as assessed by CTCAE v4.0
次要结局
- Pharmacokinetic properties of AMC303 (t1/2)(2 days)
- Pharmacokinetic properties of AMC303 (Cmax)(2 days)
- Pharmacokinetic properties of AMC303 (AUC)(2 days)
- Response rate of treatment with AMC303 in patients with metastatic solid tumors(12 months)
研究者
研究点 (7)
Loading locations...
相似试验
终止
1 期
A Safety and Tolerability Study of BDB-001 in Mild, Moderate COVID-19 PatientsCOVID-19NCT05075304Staidson (Beijing) Biopharmaceuticals Co., Ltd18
已完成
1 期
Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of TJ107 in Chinese Patients With Advanced Solid TumorsAdvanced Solid TumordNCT04001075TJ Biopharma Co., Ltd.32
已完成
1 期
A Study of LP-118 in Patients With Advanced TumorsSolid TumorLymphoma, Non-HodgkinNCT05025358Guangzhou Lupeng Pharmaceutical Company LTD.68
招募中
1 期
Study of ZGGS18 in Patients With Advanced Solid TumorsAdvanced Solid TumorNCT05584800Suzhou Zelgen Biopharmaceuticals Co.,Ltd222
尚未招募
1 期
A Study of Mitoxantrone Hydrochloride Liposome Injection Combination Therapy in Chinese Patients With Advanced Solid TumorsAdvanced Solid TumorNCT05344742CSPC ZhongQi Pharmaceutical Technology Co., Ltd.116